146 related articles for article (PubMed ID: 31868552)
41. Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A.
Prueksaritanont T; Tatosian DA; Chu X; Railkar R; Evers R; Chavez-Eng C; Lutz R; Zeng W; Yabut J; Chan GH; Cai X; Latham AH; Hehman J; Stypinski D; Brejda J; Zhou C; Thornton B; Bateman KP; Fraser I; Stoch SA
Clin Pharmacol Ther; 2017 Apr; 101(4):519-530. PubMed ID: 27943276
[TBL] [Abstract][Full Text] [Related]
42. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
[TBL] [Abstract][Full Text] [Related]
43. Combined contributions of impaired hepatic CYP2C11 and intestinal breast cancer resistance protein activities and expression to increased oral glibenclamide exposure in rats with streptozotocin-induced diabetes mellitus.
Liu H; Liu L; Li J; Mei D; Duan R; Hu N; Guo H; Zhong Z; Liu X
Drug Metab Dispos; 2012 Jun; 40(6):1104-12. PubMed ID: 22393122
[TBL] [Abstract][Full Text] [Related]
44. Roles of breast cancer resistance protein and organic anion transporting polypeptide 2B1 in gastrointestinal toxicity induced by SN-38 under inflammatory conditions.
Gulnaz A; Lee KR; Kang MJ; Chang JE; Chae YJ
Toxicol Lett; 2024 Apr; 394():57-65. PubMed ID: 38423481
[TBL] [Abstract][Full Text] [Related]
45. Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats.
Zhang D; Frost CE; He K; Rodrigues AD; Wang X; Wang L; Goosen TC; Humphreys WG
Drug Metab Dispos; 2013 Apr; 41(4):906-15. PubMed ID: 23386703
[TBL] [Abstract][Full Text] [Related]
46. Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective.
Taskar KS; Yang X; Neuhoff S; Patel M; Yoshida K; Paine MF; Brouwer KLR; Chu X; Sugiyama Y; Cook J; Polli JW; Hanna I; Lai Y; Zamek-Gliszczynski M;
Clin Pharmacol Ther; 2022 Sep; 112(3):573-592. PubMed ID: 35612761
[TBL] [Abstract][Full Text] [Related]
47. Pheophorbide A: Fluorescent Bcrp Substrate to Measure Oral Drug-Drug Interactions in Real-Time In Vivo.
Yasuda K; Ganguly S; Schuetz EG
Drug Metab Dispos; 2018 Nov; 46(11):1725-1733. PubMed ID: 30111622
[TBL] [Abstract][Full Text] [Related]
48. Astragali radix and its main bioactive compounds activate the Nrf2-mediated signaling pathway to induce P-glycoprotein and breast cancer resistance protein.
Lou Y; Guo Z; Zhu Y; Zhang G; Wang Y; Qi X; Lu L; Liu Z; Wu J
J Ethnopharmacol; 2019 Jan; 228():82-91. PubMed ID: 30243825
[TBL] [Abstract][Full Text] [Related]
49. Interactions of Oral Molecular Excipients with Breast Cancer Resistance Protein, BCRP.
Zou L; Pottel J; Khuri N; Ngo HX; Ni Z; Tsakalozou E; Warren MS; Huang Y; Shoichet BK; Giacomini KM
Mol Pharm; 2020 Mar; 17(3):748-756. PubMed ID: 31990564
[TBL] [Abstract][Full Text] [Related]
50. Rhinacanthin-C Mediated Herb-Drug Interactions with Drug Transporters and Phase I Drug-Metabolizing Enzymes.
Dunkoksung W; Vardhanabhuti N; Siripong P; Jianmongkol S
Drug Metab Dispos; 2019 Oct; 47(10):1040-1049. PubMed ID: 31399508
[TBL] [Abstract][Full Text] [Related]
51. Ginkgo biloba leaf extract suppresses intestinal human breast cancer resistance protein expression in mice: Correlation with gut microbiota.
Kim JK; Choi MS; Kim JY; Yu JS; Seo JI; Yoo HH; Kim DH
Biomed Pharmacother; 2021 Aug; 140():111712. PubMed ID: 34010745
[TBL] [Abstract][Full Text] [Related]
52. Breast Cancer Resistance Protein and Multidrug Resistance Protein 2 Determine the Disposition of Esculetin-7-O-Glucuronide and 4-Methylesculetin-7-O-Glucuronide.
Li Y; Song W; Ou X; Luo G; Xie Y; Sun R; Wang Y; Qi X; Hu M; Liu Z; Zhu L
Drug Metab Dispos; 2019 Mar; 47(3):203-214. PubMed ID: 30602435
[TBL] [Abstract][Full Text] [Related]
53. N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a "chemical knock-out equivalent" to assess the impact of efflux transporters on oral drug absorption in the rat.
Kalgutkar AS; Frederick KS; Chupka J; Feng B; Kempshall S; Mireles RJ; Fenner KS; Troutman MD
J Pharm Sci; 2009 Dec; 98(12):4914-27. PubMed ID: 19373887
[TBL] [Abstract][Full Text] [Related]
54. Using the lentiviral vector system to stably express chicken P-gp and BCRP in MDCK cells for screening the substrates and studying the interplay of both transporters.
Zhang Y; Huang J; Liu Y; Guo T; Wang L
Arch Toxicol; 2018 Jun; 92(6):2027-2042. PubMed ID: 29725709
[TBL] [Abstract][Full Text] [Related]
55. An update on expression and function of P-gp/ABCB1 and BCRP/ABCG2 in the placenta and fetus.
Han LW; Gao C; Mao Q
Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):817-829. PubMed ID: 30010462
[TBL] [Abstract][Full Text] [Related]
56. Differential effects of chrysin on nitrofurantoin pharmacokinetics mediated by intestinal breast cancer resistance protein in rats and mice.
Kawase A; Matsumoto Y; Hadano M; Ishii Y; Iwaki M
J Pharm Pharm Sci; 2009; 12(2):150-63. PubMed ID: 19732493
[TBL] [Abstract][Full Text] [Related]
57. Effect of capsaicin on breast cancer resistance protein (BCRP/Abcg2) and pharmacokinetics of probe substrates in rats.
Chen F; Wang L; Zhai X; Wang N; Qin Y; Zhu C; Wu S; Lu Y
Xenobiotica; 2022 Feb; 52(2):209-217. PubMed ID: 35345975
[TBL] [Abstract][Full Text] [Related]
58. Application of Intestinal Epithelial Cells Differentiated from Human Induced Pluripotent Stem Cells for Studies of Prodrug Hydrolysis and Drug Absorption in the Small Intestine.
Akazawa T; Yoshida S; Ohnishi S; Kanazu T; Kawai M; Takahashi K
Drug Metab Dispos; 2018 Nov; 46(11):1497-1506. PubMed ID: 30135242
[TBL] [Abstract][Full Text] [Related]
59. Ketamine Pharmacokinetics and Pharmacodynamics Are Altered by P-Glycoprotein and Breast Cancer Resistance Protein Efflux Transporters in Mice.
Ganguly S; Panetta JC; Roberts JK; Schuetz EG
Drug Metab Dispos; 2018 Jul; 46(7):1014-1022. PubMed ID: 29674491
[TBL] [Abstract][Full Text] [Related]
60. Effect of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) micelles on pharmacokinetics and intestinal toxicity of irinotecan hydrochloride: potential involvement of breast cancer resistance protein (ABCG2).
Guo S; Zhang X; Gan L; Zhu C; Gan Y
J Pharm Pharmacol; 2010 Aug; 62(8):973-84. PubMed ID: 20663031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
